Chardan Healthcare Acquisition 2 Corp.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily in the healthcare industry. The company offers no specific products or services beyond its SPAC structure, which provides merger and acquisition advisory through sponsor Chardan Capital Markets LLC; private placement investment in public equity (PIPE) financing facilitation; and public listing services for target companies seeking IPO alternatives. It targets venture-backed biopharma sector companies with experienced management, IPO readiness at valuations exceeding $250 million, and upcoming catalysts for post-combination growth, serving institutional investors, healthcare innovators, and syndicate partners in the United States and Europe. Founded in 2020 and headquartered in New York, the company is led by Executive Chairman and Chief Science Officer Gbola Amusa, MD, CFA; President, CEO, and Director Jonas Grossman; CFO and Head of Strategy George Kaufman; and COO Guy Barudin. In September 2021, CHAQ completed a business combination with Renovacor, Inc., an early-stage biotechnology firm developing adeno-associated virus (AAV)-based gene therapies for BAG3 mutation-associated cardiovascular and central nervous system diseases, raising gross proceeds of approximately $95.1 million including a $30 million PIPE and renaming the combined entity Renovacor, Inc., which traded under CHAQ ticker with headquarters in Cambridge, Massachusetts; the entity now trades as a clinical-stage gene therapy company with a market capitalization of about $55 million, low trading volume, negative earnings, and potential delisting risk amid ongoing operations focused on AAV therapies.
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - CHAQ
U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week